Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Individual bioequivalence revisited.

M L Chen1, L J Lesko

  • 1Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA.

Clinical Pharmacokinetics
|November 15, 2001
PubMed
Summary

Individual bioequivalence offers advantages over average bioequivalence for drug formulations, enabling personalized efficacy and safety assessments. The US Food and Drug Administration (FDA) continues to evaluate this approach alongside traditional methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of Significant Flavor-SU(3) Breaking in the Kaon Wave Function at 12<Q^{2}<25  GeV^{2} and Discovery of the Charmless Decay ψ(3770)→K_{S}^{0}K_{L}^{0}.

Physical review letters·2024
Same author

Measurements of All-Particle Energy Spectrum and Mean Logarithmic Mass of Cosmic Rays from 0.3 to 30 PeV with LHAASO-KM2A.

Physical review letters·2024
Same author

[Investigation of the immune profile of multiple myeloma patients achieving long-term survival after autologous stem cell transplantation].

Zhonghua nei ke za zhi·2024
Same author

Investigation of the ΔI=1/2 Rule and Test of CP Symmetry through the Measurement of Decay Asymmetry Parameters in Ξ^{-} Decays.

Physical review letters·2024
Same author

Observation of D_{s}^{+}→η^{'}μ^{+}ν_{μ}, Precision Test of Lepton Flavor Universality with D_{s}^{+}→η^{(')}l^{+}ν_{l}, and First Measurements of D_{s}^{+}→η^{(')}μ^{+}ν_{μ} Decay Dynamics.

Physical review letters·2024
Same author

Determination of the Σ^{+} Timelike Electromagnetic Form Factors.

Physical review letters·2024

Area of Science:

  • Pharmacokinetics and Drug Development
  • Regulatory Science
  • Biostatistics

Background:

  • Traditional bioequivalence assessment relies on population average comparisons between drug formulations.
  • Individual bioequivalence (IBE) was proposed to ensure consistent efficacy and safety upon switching between reference and test products.
  • The US Food and Drug Administration (FDA) has issued multiple guidance documents on IBE since 1997.

Purpose of the Study:

  • To review the scientific advantages of the individual bioequivalence criterion compared to the average bioequivalence criterion.
  • To discuss the FDA's recommendations for replicate study designs and IBE.
  • To address ongoing questions regarding the optimal use of IBE and replicate designs.

Main Methods:

  • Review of FDA guidance documents on bioequivalence criteria.

Related Experiment Videos

  • Analysis of the scientific merits of individual versus average bioequivalence.
  • Discussion of statistical methodologies and study designs, including replicate studies.

    • Main Results:

    • The individual bioequivalence criterion offers advantages such as comparing intraindividual variances and detecting subject-by-formulation interactions.
    • The FDA recommends replicate study designs for specific drug products (e.g., modified release, highly variable).
    • Despite IBE's benefits, the FDA's finalized guidance maintains the average bioequivalence criterion as primary, permitting other criteria conditionally.

    Conclusions:

    • Individual bioequivalence presents scientific advantages for assessing drug product interchangeability.
    • Further data collection and analysis from replicate studies are needed to fully resolve questions surrounding IBE.
    • The FDA's approach balances established methods with evolving scientific understanding of bioequivalence.